Research

Equity Research
BW
Babcock & Wilcox Stock Analysis (BW): Debt Maturity Looms
Jun 19, 2026
Babcock & Wilcox Enterprises (BW) is rated SELL as a turnaround story with strong backlog but weak earnings power. The key financial concern is negative operating cash flow and a 2026 debt maturity that could force a restructuring if execution slips.
Read note
Equity Research
QXO
QXO Stock Analysis (QXO): Integration Must Fix Margins
Jun 18, 2026
QXO, Inc. (QXO) is rated Hold as its valuation already prices in a recovery that has yet to show up in earnings. With operating margin still negative and levered free cash flow deeply in the red, the key question is whether the 600-branch platform can finally convert scale into profit.
Read note
Equity Research
AEHR
Aehr Test Systems Stock Analysis (AEHR): Valuation Too Rich
Jun 18, 2026
Aehr Test Systems (AEHR) earns a SELL rating as its valuation far outpaces current earnings power. Revenue is falling, cash flow remains negative, and customer concentration adds meaningful execution risk despite a strong balance sheet.
Read note
Equity Research
INCY
Incyte Stock Analysis (INCY): JAKAFI Cliff Looms
Jun 18, 2026
Incyte (INCY) is rated Hold as strong cash generation and reasonable valuation are offset by the looming 2028 JAKAFI patent cliff. The company is profitable, but investors need OPZELURA, ZYNYZ and NIKTIMVO to scale fast enough to replace legacy franchise erosion.
Read note
Equity Research
POWL
Powell Industries Stock Analysis (POWL): Valuation Leaves No Margin
Jun 18, 2026
Powell Industries (POWL) carries a HOLD rating as its backlog conversion and solid cash generation are offset by a premium valuation. With bookings down and the shares trading at elevated multiples, investors need clearer evidence of reaccelerating order flow.
Read note
SEC What Changed
CPBI, ETST, GRCE, JRSH, MDT
Grace Therapeutics (GRCE) 10-K Changes Lead 18 June 2026 Filing Roundup
Jun 18, 2026
Grace Therapeutics (GRCE) led the biggest 10-K filing change among 6 companies that filed annual reports on 18 June 2026, each compared against its prior-year…
Read note
SEC What Changed
SWBI
Smith & Wesson Brands (SWBI) 2026 10-K Analysis: MD&A Changes
Jun 17, 2026
Smith & Wesson Brands (SWBI) 2026 10-K analysis comparing the 17 June 2026 filing with its prior-year 10-K, highlighting the MD&A section’s biggest changes.
Read note
SEC What Changed
SWBI
Smith & Wesson (SWBI) 2026 10-K Analysis: MD&A Filing Changes
Jun 17, 2026
Smith & Wesson (SWBI) 2026 10-K analysis comparing MD&A changes, sales growth, tariff pressure, debt reduction, and capital allocation versus 2025.
Read note
SEC What Changed
SEC
SEC What Changed: 10-K Filing Snapshot for 16 June 2026
Jun 16, 2026
A ranked snapshot of 10-K language changes for companies that filed annual reports on 16 June 2026.
Read note
Equity Research
TER
Teradyne Stock Analysis (TER): AI Growth Priced In
Jun 15, 2026
Teradyne (TER) is rated HOLD as strong AI-driven growth and operating leverage are already offset by a steep valuation. Q1 2026 revenue rose 87% year over year, but customer concentration and rich multiples limit the upside.
Read note

Get new reports by email.

SEC filing analysis, equity deep-dives, and backtest results — delivered when published. Free, no noise.

Subscribe Free

Double opt-in · unsubscribe anytime · no advice